NovaBridge to Present Ragistomig Phase 1 Data at ESMO-IO

NovaBridge Biosciences ( (NBP) ) has provided an announcement.

On December 3, 2025, NovaBridge Biosciences announced that data from the expanded Phase 1 study of ragistomig, a bispecific antibody, will be presented at the ESMO-IO Congress on December 10, 2025. The study achieved its objective by demonstrating strong anti-tumor efficacy and improved safety in patients resistant to checkpoint inhibitors. This advancement supports further development and potential combination studies, enhancing NovaBridge’s position in the oncology field.

The most recent analyst rating on (NBP) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on NovaBridge Biosciences stock, see the NBP Stock Forecast page.

Spark’s Take on NBP Stock

According to Spark, TipRanks’ AI Analyst, NBP is a Neutral.

The overall stock score of 45 reflects I-MAB’s substantial financial challenges, particularly in terms of profitability and cash flow generation, which heavily impact its financial performance. Despite a modest technical uptrend, valuation metrics point to significant risks, with ongoing losses and a negative P/E ratio limiting its appeal. The absence of recent earnings call data or notable corporate events further solidifies the overall cautious outlook.

To see Spark’s full report on NBP stock, click here.

More about NovaBridge Biosciences

NovaBridge Biosciences is a global biotechnology platform company focused on accelerating access to innovative medicines. The company combines business development expertise with clinical development to advance breakthrough therapies. Its pipeline includes givastomig, a bispecific antibody for gastric cancer, and VIS-101, a biologic for eye conditions, among others.

Average Trading Volume: 1,346,843

Technical Sentiment Signal: Buy

Current Market Cap: $291.4M

For detailed information about NBP stock, go to TipRanks’ Stock Analysis page.